Brainstorm Cell Therapeutics Will Present A Poster Outlining The Proposed Design For A Phase 3B Trial Of Nurown In Amyotrophic Lateral Sclerosis At The MDA Clinical And Scientific Conference, On Monday
Portfolio Pulse from Benzinga Newsdesk
Brainstorm Cell Therapeutics announced it will present a poster on the design for a Phase 3b trial of NurOwn in ALS at the MDA Clinical and Scientific Conference. The trial will be a two-part, multicenter study focusing on the efficacy and safety of NurOwn in mild-to-moderate ALS patients, with a primary endpoint based on the ALSFRS-R scale.
February 27, 2024 | 11:39 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Brainstorm Cell Therapeutics will present the Phase 3b trial design of NurOwn for ALS, indicating progress in its clinical development pipeline.
The announcement of presenting a Phase 3b trial design for NurOwn in ALS at a significant conference indicates positive progress in Brainstorm Cell Therapeutics' clinical development pipeline. This could lead to increased investor confidence and potential positive movement in the stock price in the short term, as it demonstrates advancement towards regulatory approval and commercialization.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100